<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013749</url>
  </required_header>
  <id_info>
    <org_study_id>1751</org_study_id>
    <nct_id>NCT05013749</nct_id>
  </id_info>
  <brief_title>Histerectomy Vs Partial Myometrial Resection for Placenta Accreta Spectrum</brief_title>
  <acronym>RCT-PAS</acronym>
  <official_title>Hysterectomy Vs Partial Myometrial Resection for Placenta Accreta Spectrum (PAS). A Feasibility Study of a Randomized Controlled Clinical Experiment (RCT-PAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Clinica Valle del Lili</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinica Valle del Lili</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, Placenta Accreta Spectrum (PAS) has two treatment options: hysterectomy&#xD;
      (completely removing the uterus) and partial myometrial resection (resecting the part of the&#xD;
      uterus affected by this pathology).&#xD;
&#xD;
      The present study is a feasibility study of a multicenter, randomized controlled clinical&#xD;
      trial to be carried out in 3 health institutions. Patients who meet the inclusion criteria,&#xD;
      after signing the informed consent, will be taken to the surgical procedure and before the&#xD;
      start of the procedure they will be randomized to one of the two interventions, hysterectomy&#xD;
      or partial myometrial resection, intra-surgical clinical outcomes will be explored and a&#xD;
      follow-up will be carried out during the immediate post-surgical period (72 hours), in 7 to&#xD;
      12 days and at 42 days postpartum.&#xD;
&#xD;
      A sample size of 60 patients is estimated among the 3 health institutions, with an&#xD;
      approximate duration of the study of 24 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible women will receive complete information about the study. If they agree to participate in it, they will sign the informed consent for both interventions: hysterectomy and partial myometrial resection. The final modality of intervention will be decided at randomization prior to the start of the surgical procedure.&#xD;
If the diagnosis of PAS is confirmed by observing the clinical criteria endorsed by the International Federation of Gynecology and Obstetrics (FIGO), the patient's participation in the study is confirmed and the surgical procedure defined by randomization is continued, that is, one of the two arms of the study: Primary hysterectomy or Partial myometrial resection.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label study as it is not possible to conceal the surgical procedure for each arm from the operator (Treating Physician) or from the participant</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of eligible patients who agree to participate in the study.</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients who agree to participate, out of the total number of eligible patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Screening failure percentage</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of patients who entered the study but did not present macroscopic findings of placenta accreta spectrum during laparotomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with crossover between assigned study arms.</measure>
    <time_frame>24 months</time_frame>
    <description>Percentage of patients who were assigned to the partial myometrial resection arm, however, due to the severity of the injury or another factor, had to perform a hysterectomy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who completed the follow-up evaluation.</measure>
    <time_frame>24 months</time_frame>
    <description>Number of participants who completed the follow-up evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal death</measure>
    <time_frame>24 months</time_frame>
    <description>Number of maternal deaths during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-surgical bleeding volume measured in mililiters</measure>
    <time_frame>During surgery</time_frame>
    <description>Surgical bleeding calculated in milliliters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood component transfusion requirement</measure>
    <time_frame>Up to 42 days postpartum</time_frame>
    <description>If during hospitalization the patient required transfusion of some type of blood component</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median transfusion of red blood cell units (RBCU)</measure>
    <time_frame>Up to 42 days postpartum</time_frame>
    <description>Median number of units of red blood cells transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who met at least 1 Near Miss criterion</measure>
    <time_frame>Up to 42 days postpartum</time_frame>
    <description>Number of patients who met at least 1 Near Miss criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who had ureteral injuries</measure>
    <time_frame>Up to 42 days postpartum</time_frame>
    <description>Number of patients who had ureteral injuries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who had Bladder injuries</measure>
    <time_frame>Up to 42 days postpartum</time_frame>
    <description>Number of patients who had Bladder injuries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who need surgical reoperation.</measure>
    <time_frame>Up to 42 days postpartum</time_frame>
    <description>Number of patients who need surgical reoperation after index surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who were admitted to the Intensive Care Unit.</measure>
    <time_frame>Up to 42 days postpartum</time_frame>
    <description>Number of patients that required management in the Intensive Care Unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of postoperative hospital stay.</measure>
    <time_frame>Up to 42 days postpartum</time_frame>
    <description>Number of days of hospital stay after index surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Placenta Accreta</condition>
  <arm_group>
    <arm_group_label>Hysterectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Partial myometrial resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesicouterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hysterectomy</intervention_name>
    <description>Hysterectomy: An incision will be made above the level of the placenta, delivering the newborn. Uterotonics will be administered, and spontaneous delivery of the placenta will be awaited using gentle traction. The absence of spontaneous separation of the placenta will confirm the diagnosis of PAS, the patient will undergo to hysterectomy. The complete removal of the uterus will be attempted, including the cervix, the duration of the intervention and intraoperative blood loss will be recorded, as well as the damage to organs neighboring the uterus. In this arm of the study, to hysterectomy will be performed in 100% of patients</description>
    <arm_group_label>Hysterectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Partial Myometrial Resection</intervention_name>
    <description>Partial myometrial resection: The technique described by Palacios-Jaraquemada et al5. will be followed. Briefly, the uterus will be dissected to free it from the posterior wall of the bladder to the cervix. The vesico-uterine vessels will be ligated and the parametrial space will be visualized. The hysterotomy will be performed in the upper segment, immediately above the area of invasion of the myometrium. The entire invaded myometrium and the entire placenta will be removed. The uterus will repair itself in one or two layers. Intrauterine balloon tamponade will be used if indicated.</description>
    <arm_group_label>Partial myometrial resection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women over 18 years of age.&#xD;
&#xD;
          -  History of previous cesarean section and anterior placenta previa&#xD;
&#xD;
          -  Patients with prenatal diagnosis by ultrasound or MRI of PAS, regardless of the&#xD;
             suspected degree of severity of the disease.&#xD;
&#xD;
          -  Requirement for surgical management of placental accreta on a scheduled basis.&#xD;
&#xD;
          -  Patients without active vaginal bleeding in the period immediately before surgery&#xD;
             (Patients entering the operating room without active bleeding).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women without previous living children.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albaro Nieto-Calvache, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion Clinica Valle del Lili</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Albaro J Nieto-Calvache, MD</last_name>
    <phone>3319090</phone>
    <phone_ext>3025</phone_ext>
    <email>albaro.nieto@fvl.org.co</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lina M Vergara Galliadi, MD</last_name>
    <phone>3319090</phone>
    <phone_ext>3025</phone_ext>
    <email>lina.vergara@fvl.org.co</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundación Valle del Lili</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albaro Nieto-Calvache, M.D.</last_name>
      <phone>3319090</phone>
      <phone_ext>3055</phone_ext>
      <email>albaro.nieto@fvl.org.co</email>
    </contact>
    <investigator>
      <last_name>Albaro Nieto-Calvache, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <reference>
    <citation>Silver RM, Landon MB, Rouse DJ, Leveno KJ, Spong CY, Thom EA, Moawad AH, Caritis SN, Harper M, Wapner RJ, Sorokin Y, Miodovnik M, Carpenter M, Peaceman AM, O'Sullivan MJ, Sibai B, Langer O, Thorp JM, Ramin SM, Mercer BM; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol. 2006 Jun;107(6):1226-32.</citation>
    <PMID>16738145</PMID>
  </reference>
  <reference>
    <citation>D'Antonio F, Iacovella C, Bhide A. Prenatal identification of invasive placentation using ultrasound: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2013 Nov;42(5):509-17. doi: 10.1002/uog.13194. Epub 2013 Oct 2. Review.</citation>
    <PMID>23943408</PMID>
  </reference>
  <reference>
    <citation>Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017 Jul;217(1):27-36. doi: 10.1016/j.ajog.2017.02.050. Epub 2017 Mar 6. Review.</citation>
    <PMID>28268196</PMID>
  </reference>
  <reference>
    <citation>Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG. 2014 Jan;121(1):62-70; discussion 70-1. doi: 10.1111/1471-0528.12405. Epub 2013 Aug 7.</citation>
    <PMID>23924326</PMID>
  </reference>
  <reference>
    <citation>Nieto AJ, Echavarría MP, Carvajal JA, Messa A, Burgos JM, Ordoñez C, Benavidez JP, Mejía M, López L, Fernández PA, Escobar MF. Placenta accreta: importance of a multidisciplinary approach in the Colombian hospital setting. J Matern Fetal Neonatal Med. 2020 Apr;33(8):1321-1329. doi: 10.1080/14767058.2018.1517328. Epub 2018 Sep 25.</citation>
    <PMID>30153754</PMID>
  </reference>
  <reference>
    <citation>Collins SL, Alemdar B, van Beekhuizen HJ, Bertholdt C, Braun T, Calda P, Delorme P, Duvekot JJ, Gronbeck L, Kayem G, Langhoff-Roos J, Marcellin L, Martinelli P, Morel O, Mhallem M, Morlando M, Noergaard LN, Nonnenmacher A, Pateisky P, Petit P, Rijken MJ, Ropacka-Lesiak M, Schlembach D, Sentilhes L, Stefanovic V, Strindfors G, Tutschek B, Vangen S, Weichert A, Weizsäcker K, Chantraine F; International Society for Abnormally Invasive Placenta (IS-AIP). Evidence-based guidelines for the management of abnormally invasive placenta: recommendations from the International Society for Abnormally Invasive Placenta. Am J Obstet Gynecol. 2019 Jun;220(6):511-526. doi: 10.1016/j.ajog.2019.02.054. Epub 2019 Mar 5.</citation>
    <PMID>30849356</PMID>
  </reference>
  <reference>
    <citation>Palacios-Jaraquemada JM, Fiorillo A, Hamer J, Martínez M, Bruno C. Placenta accreta spectrum: a hysterectomy can be prevented in almost 80% of cases using a resective-reconstructive technique. J Matern Fetal Neonatal Med. 2020 Jan 26:1-8. doi: 10.1080/14767058.2020.1716715. [Epub ahead of print]</citation>
    <PMID>31984808</PMID>
  </reference>
  <reference>
    <citation>Allen L, Jauniaux E, Hobson S, Papillon-Smith J, Belfort MA; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Nonconservative surgical management. Int J Gynaecol Obstet. 2018 Mar;140(3):281-290. doi: 10.1002/ijgo.12409.</citation>
    <PMID>29405317</PMID>
  </reference>
  <reference>
    <citation>Sentilhes L, Kayem G, Chandraharan E, Palacios-Jaraquemada J, Jauniaux E; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Conservative management. Int J Gynaecol Obstet. 2018 Mar;140(3):291-298. doi: 10.1002/ijgo.12410.</citation>
    <PMID>29405320</PMID>
  </reference>
  <reference>
    <citation>Nieto-Calvache AJ, López-Girón MC, Messa-Bryon A, Ceballos-Posada ML, Duque-Galán M, Ríos-Posada JG, Plazas-Córdoba LA, Chancy-Castaño MM. Urinary tract injuries during treatment of patients with morbidly adherent placenta. J Matern Fetal Neonatal Med. 2021 Oct;34(19):3140-3146. doi: 10.1080/14767058.2019.1678135. Epub 2019 Oct 21.</citation>
    <PMID>31631730</PMID>
  </reference>
  <reference>
    <citation>Nieto-Calvache AJ, Vergara-Galliadi LM, Rodríguez F, Ordoñez CA, García AF, López MC, Manzano R, Velásquez J, Carbonell JP, Bryon AM, Echavarría MP, Escobar MF, Carvajal J, Benavides-Calvache JP, Burgos JM. A multidisciplinary approach and implementation of a specialized hemorrhage control team improves outcomes for placenta accreta spectrum. J Trauma Acute Care Surg. 2021 May 1;90(5):807-816. doi: 10.1097/TA.0000000000003090.</citation>
    <PMID>33496549</PMID>
  </reference>
  <reference>
    <citation>Nieto-Calvache AJ, López-Girón MC, Quintero-Santacruz M, Bryon AM, Burgos-Luna JM, Echavarría-David MP, López L, Macia-Mejia C, Benavides-Calvache JP. A systematic multidisciplinary initiative may reduce the need for blood products in patients with abnormally invasive placenta. J Matern Fetal Neonatal Med. 2020 Feb 23:1-7. doi: 10.1080/14767058.2020.1731460. [Epub ahead of print]</citation>
    <PMID>32089029</PMID>
  </reference>
  <reference>
    <citation>Nieto-Calvache AJ, Zambrano MA, Herrera NA, Usma A, Bryon AM, Benavides Calvache JP, López L, Mejía M, Palacios-Jaraquemada JM. Resective-reconstructive treatment of abnormally invasive placenta: Inter Institutional Collaboration by telemedicine (eHealth). J Matern Fetal Neonatal Med. 2021 Mar;34(5):765-773. doi: 10.1080/14767058.2019.1615877. Epub 2019 May 27.</citation>
    <PMID>31057039</PMID>
  </reference>
  <reference>
    <citation>Teixidor Viñas M, Belli AM, Arulkumaran S, Chandraharan E. Prevention of postpartum hemorrhage and hysterectomy in patients with morbidly adherent placenta: a cohort study comparing outcomes before and after introduction of the Triple-P procedure. Ultrasound Obstet Gynecol. 2015 Sep;46(3):350-5. doi: 10.1002/uog.14728.</citation>
    <PMID>25402727</PMID>
  </reference>
  <reference>
    <citation>Piñas Carrillo A, Chandraharan E. Placenta accreta spectrum: Risk factors, diagnosis and management with special reference to the Triple P procedure. Womens Health (Lond). 2019 Jan-Dec;15:1745506519878081. doi: 10.1177/1745506519878081.</citation>
    <PMID>31578123</PMID>
  </reference>
  <reference>
    <citation>Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019 Jul;146(1):20-24. doi: 10.1002/ijgo.12761. Review.</citation>
    <PMID>31173360</PMID>
  </reference>
  <reference>
    <citation>Jauniaux E, Bhide A, Kennedy A, Woodward P, Hubinont C, Collins S; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Prenatal diagnosis and screening. Int J Gynaecol Obstet. 2018 Mar;140(3):274-280. doi: 10.1002/ijgo.12408.</citation>
    <PMID>29405319</PMID>
  </reference>
  <reference>
    <citation>Jha P, Pōder L, Bourgioti C, Bharwani N, Lewis S, Kamath A, Nougaret S, Soyer P, Weston M, Castillo RP, Kido A, Forstner R, Masselli G. Society of Abdominal Radiology (SAR) and European Society of Urogenital Radiology (ESUR) joint consensus statement for MR imaging of placenta accreta spectrum disorders. Eur Radiol. 2020 May;30(5):2604-2615. doi: 10.1007/s00330-019-06617-7. Epub 2020 Feb 10.</citation>
    <PMID>32040730</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinica Valle del Lili</investigator_affiliation>
    <investigator_full_name>Albaro Nieto</investigator_full_name>
    <investigator_title>Gynecologist and Obstetrician</investigator_title>
  </responsible_party>
  <keyword>Placenta accreta</keyword>
  <keyword>Resective reconstructive treatment</keyword>
  <keyword>Hysterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Accreta</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 5, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT05013749/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 15, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT05013749/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

